Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

INFU vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INFU
InfuSystem Holdings, Inc.

Medical - Instruments & Supplies

HealthcareAMEX • US
Market Cap$206M
5Y Perf.-12.7%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$52.45B
5Y Perf.-2.7%

INFU vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INFU logoINFU
BDX logoBDX
IndustryMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$206M$52.45B
Revenue (TTM)$143M$21.92B
Net Income (TTM)$10M$1.76B
Gross Margin56.0%45.8%
Operating Margin8.3%12.4%
Forward P/E24.4x11.6x
Total Debt$3M$19.18B
Cash & Equiv.$3M$851M

INFU vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INFU
BDX
StockMay 20May 26Return
InfuSystem Holdings… (INFU)10087.3-12.7%
Becton, Dickinson a… (BDX)10097.3-2.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: INFU vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. InfuSystem Holdings, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
INFU
InfuSystem Holdings, Inc.
The Growth Play

INFU is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 6.4%, EPS growth 181.8%, 3Y rev CAGR 9.3%
  • 206.3% 10Y total return vs BDX's 72.9%
  • Lower volatility, beta 1.50, Low D/E 6.0%, current ratio 1.80x
Best for: growth exposure and long-term compounding
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 1 yrs, beta 0.66, yield 2.9%
  • Beta 0.66, yield 2.9%, current ratio 1.11x
  • 8.2% revenue growth vs INFU's 6.4%
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs INFU's 6.4%
ValueBDX logoBDXLower P/E (11.6x vs 24.4x)
Quality / MarginsBDX logoBDX8.0% margin vs INFU's 6.7%
Stability / SafetyBDX logoBDXBeta 0.66 vs INFU's 1.50
DividendsBDX logoBDX2.9% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)INFU logoINFU+115.7% vs BDX's +45.3%
Efficiency (ROA)INFU logoINFU9.5% ROA vs BDX's 3.2%, ROIC 12.5% vs 4.3%

INFU vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INFUInfuSystem Holdings, Inc.
FY 2024
Patient Services
56.6%$80M
Device Solutions
43.4%$62M
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

INFU vs BDX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINFULAGGINGBDX

Income & Cash Flow (Last 12 Months)

INFU leads this category, winning 4 of 6 comparable metrics.

BDX is the larger business by revenue, generating $21.9B annually — 152.8x INFU's $143M. Profitability is closely matched — net margins range from 8.0% (BDX) to 6.7% (INFU). On growth, INFU holds the edge at +7.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$143M$21.9B
EBITDAEarnings before interest/tax$25M$5.2B
Net IncomeAfter-tax profit$10M$1.8B
Free Cash FlowCash after capex$23M$2.6B
Gross MarginGross profit ÷ Revenue+56.0%+45.8%
Operating MarginEBIT ÷ Revenue+8.3%+12.4%
Net MarginNet income ÷ Revenue+6.7%+8.0%
FCF MarginFCF ÷ Revenue+15.9%+12.0%
Rev. Growth (YoY)Latest quarter vs prior year+7.0%+1.6%
EPS Growth (YoY)Latest quarter vs prior year+125.2%+28.8%
INFU leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — INFU and BDX each lead in 3 of 6 comparable metrics.

At 24.8x trailing earnings, BDX trades at a 24% valuation discount to INFU's 32.7x P/E. On an enterprise value basis, INFU's 8.2x EV/EBITDA is more attractive than BDX's 14.0x.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
Market CapShares × price$206M$52.4B
Enterprise ValueMkt cap + debt − cash$206M$70.8B
Trailing P/EPrice ÷ TTM EPS32.71x24.83x
Forward P/EPrice ÷ next-FY EPS est.24.38x11.59x
PEG RatioP/E ÷ EPS growth rate1.50x
EV / EBITDAEnterprise value multiple8.18x14.04x
Price / SalesMarket cap ÷ Revenue1.44x2.40x
Price / BookPrice ÷ Book value/share3.73x1.64x
Price / FCFMarket cap ÷ FCF8.64x19.64x
Evenly matched — INFU and BDX each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

INFU leads this category, winning 9 of 9 comparable metrics.

INFU delivers a 16.7% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $7 for BDX. INFU carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDX's 0.76x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs BDX's 7/9, reflecting strong financial health.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity+16.7%+6.9%
ROA (TTM)Return on assets+9.5%+3.2%
ROICReturn on invested capital+12.5%+4.3%
ROCEReturn on capital employed+14.3%+5.4%
Piotroski ScoreFundamental quality 0–987
Debt / EquityFinancial leverage0.06x0.76x
Net DebtTotal debt minus cash$241,000$18.3B
Cash & Equiv.Liquid assets$3M$851M
Total DebtShort + long-term debt$3M$19.2B
Interest CoverageEBIT ÷ Interest expense8.42x4.65x
INFU leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

INFU leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in BDX five years ago would be worth $11,037 today (with dividends reinvested), compared to $4,913 for INFU. Over the past 12 months, INFU leads with a +115.7% total return vs BDX's +45.3%. The 3-year compound annual growth rate (CAGR) favors INFU at 5.2% vs BDX's -0.1% — a key indicator of consistent wealth creation.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date+20.9%-4.9%
1-Year ReturnPast 12 months+115.7%+45.3%
3-Year ReturnCumulative with dividends+16.3%-0.4%
5-Year ReturnCumulative with dividends-50.9%+10.4%
10-Year ReturnCumulative with dividends+206.3%+72.9%
CAGR (3Y)Annualised 3-year return+5.2%-0.1%
INFU leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — INFU and BDX each lead in 1 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than INFU's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INFU currently trades 91.8% from its 52-week high vs BDX's 70.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.50x0.66x
52-Week HighHighest price in past year$11.04$205.52
52-Week LowLowest price in past year$4.67$100.31
% of 52W HighCurrent price vs 52-week peak+91.8%+70.4%
RSI (14)Momentum oscillator 0–10060.130.5
Avg Volume (50D)Average daily shares traded110K2.5M
Evenly matched — INFU and BDX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates INFU as "Buy" and BDX as "Buy". Consensus price targets imply 47.9% upside for INFU (target: $15) vs 19.4% for BDX (target: $173). BDX is the only dividend payer here at 2.88% yield — a key consideration for income-focused portfolios.

MetricINFU logoINFUInfuSystem Holdin…BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$15.00$172.85
# AnalystsCovering analysts333
Dividend YieldAnnual dividend ÷ price+2.9%
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap+5.3%+1.9%
Insufficient data to determine a leader in this category.
Key Takeaway

INFU leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallInfuSystem Holdings, Inc. (INFU)Leads 3 of 6 categories
Loading custom metrics...

INFU vs BDX: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is INFU or BDX a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 6. 4% for InfuSystem Holdings, Inc. (INFU). Becton, Dickinson and Company (BDX) offers the better valuation at 24. 8x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — INFU or BDX?

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 24.

8x versus InfuSystem Holdings, Inc. at 32. 7x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 6x.

03

Which is the better long-term investment — INFU or BDX?

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +10.

4%, compared to -50. 9% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: INFU returned +206. 3% versus BDX's +72. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — INFU or BDX?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus InfuSystem Holdings, Inc. 's 1. 50β — meaning INFU is approximately 128% more volatile than BDX relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — INFU or BDX?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 6. 4% for InfuSystem Holdings, Inc. (INFU). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, INFU leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — INFU or BDX?

InfuSystem Holdings, Inc.

(INFU) is the more profitable company, earning 10. 2% net margin versus 7. 7% for Becton, Dickinson and Company — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus 8. 3% for INFU. At the gross margin level — before operating expenses — INFU leads at 56. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is INFU or BDX more undervalued right now?

On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11.

6x forward P/E versus 24. 4x for InfuSystem Holdings, Inc. — 12. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 47. 9% to $15. 00.

08

Which pays a better dividend — INFU or BDX?

In this comparison, BDX (2.

9% yield) pays a dividend. INFU does not pay a meaningful dividend and should not be held primarily for income.

09

Is INFU or BDX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 9% yield). InfuSystem Holdings, Inc. (INFU) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +72. 9%, INFU: +206. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between INFU and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

BDX pays a dividend while INFU does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

INFU

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.1%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform INFU and BDX on the metrics below

Revenue Growth>
%
(INFU: 7.0% · BDX: 1.6%)
Net Margin>
%
(INFU: 6.7% · BDX: 8.0%)
P/E Ratio<
x
(INFU: 32.7x · BDX: 24.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.